Organon & Co. (NYSE:OGN) Shares Sold by Keeley Teton Advisors LLC

Keeley Teton Advisors LLC lessened its holdings in shares of Organon & Co. (NYSE:OGN) by 14.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,323 shares of the company’s stock after selling 7,778 shares during the period. Keeley Teton Advisors LLC’s holdings in Organon & Co. were worth $706,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. Horizon Bancorp Inc. IN increased its holdings in shares of Organon & Co. by 2,401.5% in the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after purchasing an additional 1,585 shares during the last quarter. Millstone Evans Group LLC purchased a new position in shares of Organon & Co. during the 4th quarter worth $29,000. Larson Financial Group LLC raised its holdings in shares of Organon & Co. by 345.4% during the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock worth $33,000 after acquiring an additional 1,734 shares during the period. Riverview Trust Co boosted its position in shares of Organon & Co. by 117.7% during the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock valued at $36,000 after acquiring an additional 1,292 shares during the last quarter. Finally, Versant Capital Management Inc grew its holdings in shares of Organon & Co. by 92.2% in the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock valued at $41,000 after purchasing an additional 1,324 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Stock Down 2.0 %

Organon & Co. stock opened at $10.83 on Thursday. The company has a market capitalization of $2.79 billion, a PE ratio of 3.25, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a fifty-two week low of $10.75 and a fifty-two week high of $23.10. The firm has a 50 day moving average price of $14.40 and a 200 day moving average price of $15.52.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Research analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were given a dividend of $0.28 per share. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 10.34%. Organon & Co.’s dividend payout ratio is presently 33.63%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Morgan Stanley dropped their price target on shares of Organon & Co. from $16.00 to $15.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 9th. Barclays lowered their price objective on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Finally, TD Cowen upgraded Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $20.60.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.